This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Ordering & Inventory Multiple channels for convenient orderingPfizer TruSupport gives you a variety of ways to order, track, and pay for TRUMENBAPfizer Sales Representatives also have you covered

Keeping track of your inventory can be time-consuming. That’s why Pfizer Sales Representatives have Inventory Management Tools on their iPads to help record, evaluate, and accurately forecast your stock for you. Ask a Pfizer Sales Representative about how this tool can benefit your practice.

Visit the Pfizer Prime website to learn more about ordering TRUMENBA
Learn moreLoadingAdministering TRUMENBA1
  • Before administering, shake syringe vigorously to ensure that a homogenous white suspension of TRUMENBA is obtained
  • TRUMENBA should be administered intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred site for injection is the deltoid muscle of the upper arm
  • Do not mix TRUMENBA with any other vaccine in the same syringe
How to store TRUMENBA1
  • Upon receipt, store TRUMENBA refrigerated at 2°C to 8°C (36°F to 46°F)
  • Store syringes in the refrigerator horizontally (laying flat on the shelf)
Reference:1.TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. Meningococcal Disease Reminder Program

Learn more about YourNextDose, an adherence program created to ensure your eligible patients complete the meningococcal vaccination series with TRUMENBA.

Learn more
Loading Coverage & reimbursement with TruSupport

Streamline the processes of confirming your patient's coverage for TRUMENBA

Learn how Pfizer streamlines
Loading Patient adherence

Tools to help your patients start and stay on track with the TRUMENBA series

Learn about these tools
Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TRU-USA-3196
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.